More on Johnson & Johnson's (JNJ) Q1: Worldwide Consumer sales -2.4% Y/Y to $3.6B, hurt by...


More on Johnson & Johnson's (JNJ) Q1: Worldwide Consumer sales -2.4% Y/Y to $3.6B, hurt by negative currency impact of 2.9%. Worldwide pharmaceutical sales +1.2% to $6.1B, led by strong international sales of Remicade. Worldwide Medical Devices and Diagnostics sales -0.3% to $6.4B. Sees FY12 EPS of $5.07-$5.17, above prior guidance of $5.05-$5.15. Shares +0.5% premarket. (PR)

From other sites
Comments (1)
  • Chubby Lipshitz
    , contributor
    Comments (342) | Send Message
     
    Reasonable results, nothing outstanding. With a decent efficiency program they can make further expenditure cuts and boost EPS, rather like P&G have committed to do.
    17 Apr 2012, 08:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs